A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. - Wikidata - wikimedia - TriplyDB

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

http://www.wikidata.org/entity/Q34325583

about

Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives Genomic profiling in luminal breast cancer Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women Prospective Validation of a 21-Gene Expression Assay in Breast Cancer Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer.A breast cancer gene signature for indolent disease.Biological subtypes of breast cancer: Prognostic and therapeutic implications.The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer Breast cancer in young women: special considerations in multidisciplinary care.Equivalence of MammaPrint array types in clinical trials and diagnostics.Multigene prognostic tests in breast cancer: past, present, future Big data and computational biology strategy for personalized prognosis.The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.Molecular profiling for breast cancer: a comprehensive review.Long-term impact of the 70-gene signature on breast cancer outcome.Mammographic screening detects low-risk tumor biology breast cancers.Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.Molecular tests as prognostic factors in breast cancer.Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.Hurdles on the road to personalized medicine.Genomic medicine and risk prediction across the disease spectrum.Gene expression-based prognostic and predictive tools in breast cancer.Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization.Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.Biomarker assessment and molecular testing for prognostication in breast cancer.Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.Clinical utility of gene-expression signatures in early stage breast cancer.GENE EXPRESSION PROFILING AND EXPANDED IMMUNOHISTOCHEMISTRY TESTS TO GUIDE SELECTION OF CHEMOTHERAPY REGIMENS IN BREAST CANCER MANAGEMENT: A SYSTEMATIC REVIEW.Nuclear SIPA1 activates integrin β1 promoter and promotes invasion of breast cancer cells.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.Internet tools to enhance breast cancer care.

P2860

Q26768119-69FF779B-6331-41EE-81E0-274E92DA3FD0 Q26862681-09FF9A5C-A460-42D8-8383-A4CA8C786EBD Q28077637-997AD93B-F9E7-4C28-A8A2-18953504FD6D Q29011698-A6AA7B47-5D84-4057-9E03-3C6E123E5FBA Q30543788-1282683C-C81A-4E3B-848B-D2C6DFC66ADF Q33613591-E16FF480-4419-4F18-9A42-8439BB6D479B Q33651520-61C08882-038A-4530-82AF-E14CBED8DDB0 Q33657870-7392323E-7440-49DB-A7C1-D461C36AFA53 Q33843780-FB8F1EB7-5B0B-4B38-9D76-98E7051A8533 Q34023695-397D4F4F-A0F0-488A-B8B5-60A926A0F68A Q34113489-8EF1730B-E5AE-40AF-BB76-4A465F3EB2B5 Q34306522-615C777B-FB02-4844-92D0-5CE560C6178D Q34519347-446540E1-F2B8-4C50-A0BA-496DFFFBABBD Q35018599-E1CFF326-8720-488D-912C-1478C054D355 Q36031260-6928748E-2491-4AE0-A02D-F1C5469D891E Q36462893-3213E942-FA3E-45A6-B308-B6EB6FB5A695 Q37214217-5B1EBF89-DFEA-4F66-B1FC-05B6134D65B1 Q37302484-1B6E4808-18DE-4F06-87CB-77BE97218AED Q37534934-2DE059DF-1C37-4279-8B1E-7974ED2B22FA Q37583102-88B3137C-D8C2-455F-A6C7-046BF6D1FE87 Q37711677-75F3809E-BC39-4D11-9400-C5F420EDAF2F Q38184381-24937BEE-33A1-4507-8175-2E25FAA99197 Q38232507-CEFBC829-E84D-460E-9F9B-A20561CBF572 Q38250141-8FBAB857-1637-4CFF-8400-ABF290C8D70F Q38322338-CAAD2140-C512-4A4B-8183-B514D69A62DE Q38421414-53D94175-7533-4C47-9E37-680F9D7C720B Q38551397-DB9BC15C-C450-4800-93B8-D5FE475E889F Q38632574-00614C1B-DC30-4F2B-8C06-C19D6A710D90 Q38690101-DB029F86-ABE1-4337-88D9-A3242BDC122A Q38696790-2BAC3C1D-57E4-4C6C-8192-B45612DB76D3 Q38745404-AAEEFBBF-6715-4D73-9697-D672DD0A9440 Q38754717-15517A9C-50D4-4641-B2F2-7D2F7E27A4FD Q38795484-DD610DCD-5FED-49C7-AF34-C7B121DBD3B4 Q39007386-9B502DDE-BBB3-4496-AF4E-BD9799E26FBD Q39187437-67C9BB2B-D01D-41E3-9964-4BDF44ED5511 Q39532008-4724C8A0-7938-400F-8B0E-88C78D8B788A Q40808798-020B5108-44FC-43A4-89C1-468278AD055D Q41113513-E56FD5C0-64AE-486B-81FC-E0DA08501E2B Q41545259-80147A07-8A43-4708-BF81-86A227280B4C Q42334186-5A4081D0-0819-446C-A8A4-C7BD12B66ADD

P2860

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

http://www.wikidata.org/entity/Q34325583

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A prospective evaluation of a ...... he observational RASTER study.

@ast

A prospective evaluation of a ...... he observational RASTER study.

@en

A prospective evaluation of a ...... he observational RASTER study.

@nl

type

label

A prospective evaluation of a ...... he observational RASTER study.

@ast

A prospective evaluation of a ...... he observational RASTER study.

@en

A prospective evaluation of a ...... he observational RASTER study.

@nl

prefLabel

A prospective evaluation of a ...... he observational RASTER study.

@ast

A prospective evaluation of a ...... he observational RASTER study.

@en

A prospective evaluation of a ...... he observational RASTER study.

@nl

P1433

Q34325583-B47FD604-C501-45C7-9018-0803FA0B2787

P1476

Q34325583-DB87ACCF-9777-46FA-A49B-37197AA0C514

P2093

Q34325583-09572CEA-355C-4A65-BDF2-406252EA1D58

Q34325583-30B880DD-0D72-4561-8B3A-8DF29E2B760A

Q34325583-41D86CE1-83E7-4DE1-8DDE-F427A65C0FEE

Q34325583-6FB875BD-8AEF-49D2-807C-EF5CE5B7F69D

Q34325583-812B6083-1922-4DD3-ACA0-BD2D08C68F8B

Q34325583-B56B4293-3423-46F3-9776-F89E252D39AD

Q34325583-BDEFC21F-8F7B-4226-A40F-66D0E71CD2DF

Q34325583-C38C7BF8-836C-4515-BFC4-79C0486EB954

Q34325583-C7167B69-0BD2-4D40-8DC9-8EEDA29FB015

Q34325583-E63EA701-02E2-40C6-9D7F-DAB787792707

P2860

Q34325583-03704646-A901-4873-B4F0-E0D8238DF695

Q34325583-0F2C3983-B10D-441A-8AB4-4C4A36E12C7E

Q34325583-10F73DD8-AC65-45B8-B5AA-70CCCEC79428

Q34325583-30D7493B-1F4F-4198-A100-539D2C9F93B1

Q34325583-34985D39-FB22-4E17-A82C-3C771B6E58FF

Q34325583-373BA8A7-FFBB-4663-BEE8-1A551472D085

Q34325583-5DB7B97C-89CC-4D92-AA65-991758CFCE30

Q34325583-67C22C46-FAEA-4AD7-B454-1C04C13D6E3C

Q34325583-8830020F-378F-409D-9A05-2FC78EADEA59

Q34325583-A4C306A1-4B12-4008-8609-1F79B42E6859

P304

Q34325583-6D5D1C5A-B5D7-47CD-A588-DF3C10535966

P31

Q34325583-047F1F3F-2351-41CC-B629-4E457CB8E9A0

P356

Q34325583-04BA267E-2F08-4BFD-97D6-68EAE7889147

P433

Q34325583-081FCBD5-5644-4637-95B8-5BD3167AD51D

P478

Q34325583-2CF16352-1EBF-412B-888B-A6C4A94EAC42

P50

Q34325583-EF10A74B-B66D-4A2F-A973-35C36B5B1830

P577

Q34325583-CAD2B8BE-B654-4967-ABA7-C01C8396ADE0

P5875

Q34325583-760E9832-88D6-4F4D-B2F6-9F7845268A13

P698

Q34325583-61926805-C1A8-47E9-AF57-BCFA01F5EF27

P932

Q34325583-0957B69F-BBF9-4514-BD0C-FF912946D2D1

P356

P1433

International Journal of Cancer

P1476

A prospective evaluation of a ...... he observational RASTER study.

@en

P2093

C A Drukker

http://www.w3.org/2001/XMLSchema#string

E J T Rutgers

http://www.w3.org/2001/XMLSchema#string

G S Sonke

http://www.w3.org/2001/XMLSchema#string

H van Tinteren

http://www.w3.org/2001/XMLSchema#string

J M Bueno-de-Mesquita

http://www.w3.org/2001/XMLSchema#string

J Wesseling

http://www.w3.org/2001/XMLSchema#string

L J van 't Veer

http://www.w3.org/2001/XMLSchema#string

M Knauer

http://www.w3.org/2001/XMLSchema#string

R M H Roumen

http://www.w3.org/2001/XMLSchema#string

S C Linn

http://www.w3.org/2001/XMLSchema#string

P2860

A gene-expression signature as a predictor of survival in breast cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Commercialized multigene predictors of clinical outcome for breast cancer.

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

Quality of Life Differences between Younger and Older Breast Cancer Patients.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

P304

929-936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.28082

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P50

Marc van de Vijver

P577

2013-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235392214

http://www.w3.org/2001/XMLSchema#string

P698

23371464

http://www.w3.org/2001/XMLSchema#string

P932

3734625

http://www.w3.org/2001/XMLSchema#string